F. Stephen Hodi

F. Stephen Hodi led the landmark phase III clinical trial that established ipilimumab as the first immune checkpoint inhibitor to demonstrate improved overall survival in advanced melanoma, and contributed to subsequent combination IO trials building on this foundation. His research on the CheckMate 067 trial with Jedd Wolchok established ipilimumab plus nivolumab as a superior regimen to either single agent, with over 50% 5-year overall survival in previously untreated advanced melanoma. He has characterized the spectrum of immune-related adverse events from combination checkpoint blockade and their management, developing the clinical framework now used for toxicity grading and treatment. His translational research on tumor-infiltrating immune cell profiling has contributed to understanding mechanisms underlying combination IO efficacy and developing predictive biomarkers.